100. Swales JD. Guidelines for treating hypertension: improved care or retarded progress? *Am J Hypertens* 1994 Oct; 7 (Pt 1): 873-6
101. Weber MA. Controversies in the diagnosis and treatment of hypertension: a personal review of JNC V. *Am J Cardiol* 1993; 72: 3H-9H
102. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. *Eur Heart J* 1994 Oct; 15: 1300-31
103. Gong L, Zhang W, Zhu Y, et al. Prospective study of the effect of nifedipine on the cardiovascular complications in the elderly hypertensives [abstract no. P101]. *J Hypertens* 1992; 10 Suppl. 4: S132
104. Borchard U. Calcium antagonists in comparison: view of the pharmacologist. *J Cardiovasc Pharmacol* 1994; 24 Suppl. 2: S85-91
105. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. *Circulation* 1995; 92: 1326-31
106. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. *JAMA* 1995; 274 (8): 620-5
107. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. *Arch Intern Med* 1995 Nov 13; 155: 2150-6
108. Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side. *Arch Intern Med* 1995 Nov 13; 155: 2157-61
109. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. *Ann Intern Med* 1995; 123 (11): 888-9
110. Anon. Results of the DEFIANT-II study with nisoldipine: effective and safe in the treatment of myocardial infarction [in German]. *Munch Med Wochenschrift* 1995 Aug 23; 137 (42) Suppl.
111. Cohn JN, Ziesche SM, Loss LE, et al. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT VIII [abstract]. *Circulation* 1995; 92 (8) Suppl. 1: I-143
112. O'Connor CM, Belkin RN, Carson PE, et al. Effect of amlodipine on mode of death in severe chronic heart failure: the PRAISE trial [abstract]. *Circulation* 1995; 92 Suppl. 1: I-143

Correspondence: *Greg L. Plosker*, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Errata

Vol. 51, No. 4, pages 594-611: References in tables III to IX are incorrectly numbered.

For tables III to VI, add 1 to the cited number to obtain the correct reference; e.g. in table IV, Gorlero et al.^[54] should read Gorlero et al.^[55].

For tables VII and VIII, add 2 to the cited number to obtain the correct reference; e.g. in table VII, Pariser et al.^[114] should read Pariser et al.^[116].

For table IX, reference 3 is correct but the remainder require change. References [61], [63] and [73] should read [62], [64] and [74]. Add 2 to the remaining cited numbers to obtain the correct references; e.g. reference [200] should read [202].

page 599: In the study by Bräutigam et al. 1995 in table V, footnote f should be deleted from the column labelled 'mycological cure'.

[*Haria M, Bryson HM, Goa KL. Itraconazole: a review of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51 (4): 585-620*]

Vol. 51, No. 4, page 660: In the summary, the second sentence of the Physical and Pharmacodynamic Properties paragraph should read: 'Its anaesthetic potency is ≈50% less than that of isoflurane but ≈3-fold more than that of desflurane'.

page 663: In section 1, the fourth sentence of the first paragraph should read "... is ≈50% less than that of isoflurane but ≈3-fold more than that of desflurane (table I)'.

[*Patel SS, Goa KL. Sevoflurane: a review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Drugs 1996; 51 (4): 658-700*]